Market Research Logo

Global Multi Infarct Dementia Market Insights, Opportunity Analysis, Market Shares and Forecast, 2016 - 2022

Global Multi Infarct Dementia Market Insights, Opportunity Analysis, Market Shares and Forecast, 2016 - 2022

Global Multi Infarct Dementia Market Research Report 2016 by OBRC, is an extensive study on present state of the Multi Infarct Dementia Market. The global multi-infarct dementia is estimated to reach $1,3400million at CAGR 12.7% during 2016-2022.

Multi infarct dementia is a common cause of memory loss among the elderly people between age group 55 to 75 years. Multi infarct dementia is triggered by multiple strokes to the brain it is also called as vascular dementia. According to National Institute of Health epidemiological study, multi infarct dementia accounts for over 20% dementia cases among people with age group above 65 years. Growing geriatric population in the world and rising number of brain strokes would escalate the incidence of multi infarct dementia. American Stoke Association, in its 2016 epidemiological report on stroke, projected the global prevalence rate of stroke accounted for one in five per 1000 person. In U.S. nearly 800,000 people have a stroke every year, according to American Stroke Association. By 2030 stroke prevalence will rise around 20% more than 2012 level. There are no practicable treatment options for multi infarct dementia, other than early diagnosis and routine therapy.

Early diagnosis involves assessing individual cognitive ability, medical history, brain scans like computed topography (CT) or magnetic resonance imaging (MRI) scans. Changing regulatory compliance rules of different countries pose a challenge for market growth in the region.

Aging countries like Japan, Italy, Greece and Germany are the major markets for multi-infarct dementia. North America has been the dominant market for multi infarct dementia in last two fiscal years (2015 & 2016) followed by Europe. Asia Pacific and Latin America is the fastest growing multi infarct dementia market for the forecasted period.

Increasing geriatric population, rising prevalence of strokes and increasing healthcare spending are the growth drivers discussed in multi-infarct dementia market research report. Emerging Economies and technological advancements in inhibitors are opportunities in deliberated in multi-infarct dementia market report for the forecasted period.

Varying regulatory environment of different countries and unavailability of treatment therapy are the restraining issues discussed in multi infarct dementia market report. Lack of awareness about dementia as a disease is a challenge for the market growth.

The research report is segmented in terms of pharmacological treatment and causes of dementia. The pharmacological treatment segment is further sub segmented into cholinesterase inhibitors, memantine, nimodipine, hydergine, and cytidine 5’-diphosphocholine (CDP-Choline), and other drug classes like selective serotonin reuptake inhibitors, calcium channel blockers, and angiotensin-converting-enzyme inhibitors. Cholinesterase inhibitors are further divided into donepezil, galantamine, and rivastigmine. Causes of dementia are further classified into anaemia, brain tumour, chronic infection, depression, thyroid disease, vitamin deficiency, and drug intoxication.

Some of the leading companies are Accelerys Inc., Affymetrix Ltd., Agilent Technologies., Celera Corporation., DNAexus Ltd., Forest Laboratories Inc., Geneva Bioinformatics., GVK Biosciences Ltd., IBM Life Science Ltd., Illumina Inc., Janssen Pharmaceuticals Inc., Life Technologies Corporation., Novartis Pharmaceutical Corporation., Pfizer Inc., and Siegen Inc. The report provides comprehensive information like company profile, sales, revenue, market share and contact information.

Joint ventures, agreements, partnerships, collaborations, expansion in different countries, and strengthening supply chain network with distributors are some of the strategies taken by pioneers in multi-infarct dementia market, to increase their global presence. Research & development investments are high with the urge to develop quality and environmental friendly products. Amarantus biosciences Inc., is currently undergoing its third phase clinical trials on drug Eltoprazine, after successful phase two trials on December 2015. Small pharmaceutical firms with unique and differentiated assets are driving innovation in multi-infarct dementia market.

The research report analysed multi-infarct dementia market geographically. Region wise the report is segmented as North America, Europe, Asia Pacific, and Rest of the World.

North America is the largest market for multi-infarct dementia market followed by Europe. Increasing cases of multi infarct dementia and growing geriatric population are the factors driving multi-infarct dementia market in the region. Multi-Infarct Dementia accounts for 30% of all dementia cases in North America and Europe.

Asia Pacific is the fastest growing multi-infarct dementia market for the forecasted period. Rising geriatric population, increased healthcare spending, and changing healthcare reforms are the factors driving multi-infarct dementia market in the region for the forecasted period. Multi-Infarct dementia accounts for over 50% of the dementia cases in Japan.

Please note: The delivery time for the electronic version of this report is between 1-3 business days to allow the preparation of an updated version prior to dispatch.


1. INTRODUCTION
1.1. EXECUTIVE SUMMARY
1.2. MARKET SCOPE
2. MARKET OVERVIEW
2.1. GLOBAL MULTI-INFARCT DEMENTIA MARKET: EVOLUTION & TRANSITION
2.2. INDUSTRY STRUCTURE
2.3. MANUFACTURING PROCESS
2.4. REGULATORY FRAMEWORK
2.5. TOTAL MARKET ANALYSIS
2.5.1. TOP 5 FINDINGS
2.5.2. TOP 5 OPPORTUNITY MARKETS
2.5.3. TOP 5 COMPANIES
2.5.4. TOP 3 COMPETITIVE STRATEGIES
2.6. ESTIMATION ANALYSIS
2.7. STRATEGIC ANALYSIS
2.7.1. INVESTMENT VS. ADOPTION MODEL
2.7.2. 360 DEGREE INDUSTRY ANALYSIS
2.7.3. PORTERS 5 FORCE MODEL
2.7.4. SEE-SAW ANALYSIS
2.7.5. PRICING ANALYSIS
2.7.6. CONSUMER ANALYSIS AND KEY BUYING CRITERIA
2.7.7. ROI ANALYSIS
2.7.8. GAP ANALYSIS
2.8. COMPETITIVE ANALYSIS
2.8.1. KEY STRATEGIES AND ANALYSIS
2.8.2. MARKET SHARE
2.8.3. TOP COMPANY ANALYSIS
2.9. STRATEGIC RECOMMENDATIONS & KEY CONCLUSIONS
2.9.1. INVESTMENT OPPORTUNITIES BY REGIONS
2.9.2. OPPORTUNITIES IN EMERGING APPLICATIONS
2.9.3. INVESTMENT OPPORTUNITY IN FASTEST GROWING SEGMENT
3. MARKET DETERMINANTS
3.1. MARKET DRIVERS & MARKET IMPACT
3.1.1. INCREASING GERIATRIC POPULATION
3.1.2. RISING PREVALENCE OF STROKES
3.1.3. INCREASING HEALTHCARE SPENDING
3.1.4. RISING DEMAND FOR DIAGNOSTIC PRODUCTS
3.1.5. RISING INVESTMENT IN RESEARCH
3.2. MARKET RESTRAINTS & MARKET IMPACT
3.2.1. VARYING REGULATORY ENVIRONMENT OF DIFFERENT COUNTRIES
3.2.2. UNAVAILABILITY OF TREATMENT THERAPY
3.2.3. SUSTAINABILITY IN MARKET
3.3. MARKET OPPORTUNITIES
3.3.1. EMERGING ECONOMIES
3.3.2. TECHNOLOGICAL ADVANCEMENTS IN INHIBITORS
3.4. MARKET CHALLENGES
3.4.1. LACK OF AWARENESS ABOUT DEMENTIA
3.4.2. HIGH COST OF RESEARCH AND DEVELOPMENT
3.4.3. INCREASING GERIATRIC MEDICINE MARKETS
4. MARKET SEGMENTATION
4.1. GLOBAL MULTI-INFARCT DEMENTIA MARKET BY PHARMACOLOGICAL TREATMENT 2014-2022 ($ MILLION)
4.1.1. MARKET DEFINITION AND SCOPE
4.1.2. DECISION SUPPORT DATABASE & ESTIMATION METHODOLOGY
4.1.3. COMPARATIVE ANALYSIS ACROSS MARKET SEGMENTS
4.1.4. OPPORTUNITY MATRIX
4.1.5. MARKET SEGMENTATION
4.1.5.1. CHOLINESTERASE INHIBITORS 2014-2022 ($ MILLION)
4.1.5.1.1. APPLICATIONS
4.1.5.1.2. ADOPTION SCENARIO & MARKET DETERMINANTS
4.1.5.1.3. MARKET ESTIMATIONS AND FORECASTS 2014-2022 ($ MILLION)
4.1.5.1.4. TOP PLAYERS & KEY PRODUCTS
4.1.5.1.5. KEY CONCLUSIONS
4.1.5.1.6. CHOLINESTERASE INHIBITORS BY SUB-SEGMENT
4.1.5.1.6.1. DONEPEZIL
4.1.5.1.6.2. GALANTAMINE
4.1.5.1.6.3. RIVASTIGMINE
4.1.5.2. MEMANTINE 2014-2022 ($ MILLION)
4.1.5.2.1. APPLICATIONS
4.1.5.2.2. ADOPTION SCENARIO & MARKET DETERMINANTS
4.1.5.2.3. MARKET ESTIMATIONS AND FORECASTS 2014-2022 ($ MILLION)
4.1.5.2.4. TOP PLAYERS & KEY PRODUCTS
4.1.5.2.5. KEY CONCLUSIONS
4.1.5.3. NIMODIPINE 2014-2022 ($ MILLION)
4.1.5.3.1. APPLICATIONS
4.1.5.3.2. ADOPTION SCENARIO & MARKET DETERMINANTS
4.1.5.3.3. MARKET ESTIMATIONS AND FORECASTS 2014-2022 ($ MILLION)
4.1.5.3.4. TOP PLAYERS & KEY PRODUCTS
4.1.5.3.5. KEY CONCLUSIONS
4.1.5.4. HYDERGINE 2014-2022 ($ MILLION)
4.1.5.4.1. APPLICATIONS
4.1.5.4.2. ADOPTION SCENARIO & MARKET DETERMINANTS
4.1.5.4.3. MARKET ESTIMATIONS AND FORECASTS 2014-2022 ($ MILLION)
4.1.5.4.4. TOP PLAYERS & KEY PRODUCTS
4.1.5.4.5. KEY CONCLUSIONS
4.1.5.5. CYTIDINE 5’-DIPHOSPHOCHOLINE (CDP-CHOLINE) 2014-2022 ($ MILLION)
4.1.5.5.1. APPLICATIONS
4.1.5.5.2. ADOPTION SCENARIO & MARKET DETERMINANTS
4.1.5.5.3. MARKET ESTIMATIONS AND FORECASTS 2014-2022 ($ MILLION)
4.1.5.5.4. TOP PLAYERS & KEY PRODUCTS
4.1.5.5.5. KEY CONCLUSIONS
4.1.5.6. OTHER DRUG CLASSES 2014-2022 ($ MILLION)
4.1.5.6.1. APPLICATIONS
4.1.5.6.2. ADOPTION SCENARIO & MARKET DETERMINANTS
4.1.5.6.3. MARKET ESTIMATIONS AND FORECASTS 2014-2022 ($ MILLION)
4.1.5.6.4. TOP PLAYERS & KEY PRODUCTS
4.1.5.6.5. KEY CONCLUSIONS
4.2. GLOBAL MULTI-INFARCT DEMENTIA MARKET BY CAUSES OF DEMENTIA 2014-2022 ($ MILLION)
4.2.1. MARKET DEFINITION AND SCOPE
4.2.2. DECISION SUPPORT DATABASE & ESTIMATION METHODOLOGY
4.2.3. COMPARATIVE ANALYSIS ACROSS MARKET SEGMENTS
4.2.4. OPPORTUNITY MATRIX
4.2.5. MARKET SEGMENTATION
4.2.5.1. ANAEMIA 2014-2022 ($ MILLION)
4.2.5.1.1. APPLICATIONS
4.2.5.1.2. ADOPTION SCENARIO & MARKET DETERMINANTS
4.2.5.1.3. MARKET ESTIMATIONS AND FORECASTS 2014-2022 ($ MILLION)
4.2.5.1.4. TOP PLAYERS & KEY PRODUCTS
4.2.5.1.5. KEY CONCLUSIONS
4.2.5.2. BRAIN TUMOR 2014-2022 ($ MILLION)
4.2.5.2.1. APPLICATIONS
4.2.5.2.2. ADOPTION SCENARIO & MARKET DETERMINANTS
4.2.5.2.3. MARKET ESTIMATIONS AND FORECASTS 2014-2022 ($ MILLION)
4.2.5.2.4. TOP PLAYERS & KEY PRODUCTS
4.2.5.2.5. KEY CONCLUSIONS
4.2.5.3. CHRONIC INFECTION 2014-2022 ($ MILLION)
4.2.5.3.1. APPLICATIONS
4.2.5.3.2. ADOPTION SCENARIO & MARKET DETERMINANTS
4.2.5.3.3. MARKET ESTIMATIONS AND FORECASTS 2014-2022 ($ MILLION)
4.2.5.3.4. TOP PLAYERS & KEY PRODUCTS
4.2.5.3.5. KEY CONCLUSIONS
4.2.5.4. DEPRESSION 2014-2022 ($ MILLION)
4.2.5.4.1. APPLICATIONS
4.2.5.4.2. ADOPTION SCENARIO & MARKET DETERMINANTS
4.2.5.4.3. MARKET ESTIMATIONS AND FORECASTS 2014-2022 ($ MILLION)
4.2.5.4.4. TOP PLAYERS & KEY PRODUCTS
4.2.5.4.5. KEY CONCLUSIONS
4.2.5.5. THYROID DISEASE 2014-2022 ($ MILLION)
4.2.5.5.1. APPLICATIONS
4.2.5.5.2. ADOPTION SCENARIO & MARKET DETERMINANTS
4.2.5.5.3. MARKET ESTIMATIONS AND FORECASTS 2014-2022 ($ MILLION)
4.2.5.5.4. TOP PLAYERS & KEY PRODUCTS
4.2.5.5.5. KEY CONCLUSIONS
4.2.5.6. VITAMIN DEFICIENCY 2014-2022 ($ MILLION)
4.2.5.6.1. APPLICATIONS
4.2.5.6.2. ADOPTION SCENARIO & MARKET DETERMINANTS
4.2.5.6.3. MARKET ESTIMATIONS AND FORECASTS 2014-2022 ($ MILLION)
4.2.5.6.4. TOP PLAYERS & KEY PRODUCTS
4.2.5.6.5. KEY CONCLUSIONS
4.2.5.7. DRUG INTOXICATION 2014-2022 ($ MILLION)
4.2.5.7.1. APPLICATIONS
4.2.5.7.2. ADOPTION SCENARIO & MARKET DETERMINANTS
4.2.5.7.3. MARKET ESTIMATIONS AND FORECASTS 2014-2022 ($ MILLION)
4.2.5.7.4. TOP PLAYERS & KEY PRODUCTS
4.2.5.7.5. KEY CONCLUSIONS
5. COMPETITIVE LANDSCAPE
5.1. KEY STRATEGIES
5.1.1. LIST OF M&A
5.1.2. LIST OF JV
5.1.3. LIST OF PRODUCT LAUNCHES
5.1.4. LIST OF PARTNERSHIP
5.2. TOP 10 COMPANY ANALYSIS – DASHBOARD
6. GLOBAL MULTI-INFARCT DEMENTIA MARKET BY REGION (REVENUE ANALYSIS) 2014-2022 ($ MILLION)
6.1. DECISION SUPPORT DATABASE & ESTIMATION METHODOLOGY
6.2. COMPARATIVE ANALYSIS ACROSS MARKET SEGMENTS
6.3. OPPORTUNITY MATRIX
6.4. GEOGRAPHIC SEGMENTATION
6.4.1. NORTH AMERICA
6.4.1.1. INDUSTRY APPLICATION ANALYSIS
6.4.1.2. TOP COUNTRY ANALYSIS
6.4.1.2.1. U.S.
6.4.1.2.1.1. MARKET ESTIMATIONS AND FORECASTS 2014-2022 ($ MILLION)
6.4.1.2.1.2. MARKET REVENUES 2014-2022 ($ MILLION)
6.4.1.2.1.3. PRICE ANALYSIS
6.4.1.2.1.4. TOP PLAYERS & KEY PRODUCTS
6.4.1.2.1.5. KEY CONCLUSIONS
6.4.1.2.2. CANADA
6.4.1.2.2.1. MARKET ESTIMATIONS AND FORECASTS 2014-2022 ($ MILLION)
6.4.1.2.2.2. MARKET REVENUES 2014-2022 ($ MILLION)
6.4.1.2.2.3. PRICE ANALYSIS
6.4.1.2.2.4. TOP PLAYERS & KEY PRODUCTS
6.4.1.2.2.5. KEY CONCLUSIONS
6.4.2. EUROPE
6.4.2.1. INDUSTRY APPLICATION ANALYSIS
6.4.2.2. TOP COUNTRY ANALYSIS
6.4.2.2.1. UK
6.4.2.2.1.1. MARKET ESTIMATIONS AND FORECASTS 2014-2022 ($ MILLION)
6.4.2.2.1.2. MARKET REVENUES 2014-2022 ($ MILLION)
6.4.2.2.1.3. PRICE ANALYSIS
6.4.2.2.1.4. TOP PLAYERS & KEY PRODUCTS
6.4.2.2.1.5. KEY CONCLUSIONS
6.4.2.2.2. FRANCE
6.4.2.2.2.1. MARKET ESTIMATIONS AND FORECASTS 2014-2022 ($ MILLION)
6.4.2.2.2.2. MARKET REVENUES 2014-2022 ($ MILLION)
6.4.2.2.2.3. PRICE ANALYSIS
6.4.2.2.2.4. TOP PLAYERS & KEY PRODUCTS
6.4.2.2.2.5. KEY CONCLUSIONS
6.4.2.2.3. GERMANY
6.4.2.2.3.1. MARKET ESTIMATIONS AND FORECASTS 2014-2022 ($ MILLION)
6.4.2.2.3.2. MARKET REVENUES 2014-2022 ($ MILLION)
6.4.2.2.3.3. PRICE ANALYSIS
6.4.2.2.3.4. TOP PLAYERS & KEY PRODUCTS
6.4.2.2.3.5. KEY CONCLUSIONS
6.4.2.2.4. REST OF EUROPE
6.4.2.2.4.1. MARKET ESTIMATIONS AND FORECASTS 2014-2022 ($ MILLION)
6.4.2.2.4.2. MARKET REVENUES 2014-2022 ($ MILLION)
6.4.2.2.4.3. PRICE ANALYSIS
6.4.2.2.4.4. TOP PLAYERS & KEY PRODUCTS
6.4.2.2.4.5. KEY CONCLUSIONS
6.4.3. ASIA PACIFIC
6.4.3.1. INDUSTRY APPLICATION ANALYSIS
6.4.3.2. TOP COUNTRY ANALYSIS
6.4.3.2.1. CHINA
6.4.3.2.1.1. MARKET ESTIMATIONS AND FORECASTS 2014-2022 ($ MILLION)
6.4.3.2.1.2. MARKET REVENUES 2014-2022 ($ MILLION)
6.4.3.2.1.3. PRICE ANALYSIS
6.4.3.2.1.4. TOP PLAYERS & KEY PRODUCTS
6.4.3.2.1.5. KEY CONCLUSIONS
6.4.3.2.2. INDIA
6.4.3.2.2.1. MARKET ESTIMATIONS AND FORECASTS 2014-2022 ($ MILLION)
6.4.3.2.2.2. MARKET REVENUES 2014-2022 ($ MILLION)
6.4.3.2.2.3. PRICE ANALYSIS
6.4.3.2.2.4. TOP PLAYERS & KEY PRODUCTS
6.4.3.2.2.5. KEY CONCLUSIONS
6.4.3.2.3. JAPAN
6.4.3.2.3.1. MARKET ESTIMATIONS AND FORECASTS 2014-2022 ($ MILLION)
6.4.3.2.3.2. MARKET REVENUES 2014-2022 ($ MILLION)
6.4.3.2.3.3. PRICE ANALYSIS
6.4.3.2.3.4. TOP PLAYERS & KEY PRODUCTS
6.4.3.2.3.5. KEY CONCLUSIONS
6.4.3.2.4. REST OF ASIA PACIFIC
6.4.3.2.4.1. MARKET ESTIMATIONS AND FORECASTS 2014-2022 ($ MILLION)
6.4.3.2.4.2. MARKET REVENUES 2014-2022 ($ MILLION)
6.4.3.2.4.3. PRICE ANALYSIS
6.4.3.2.4.4. TOP PLAYERS & KEY PRODUCTS
6.4.3.2.4.5. KEY CONCLUSIONS
6.4.4. REST OF THE WORLD
6.4.4.1. INDUSTRY APPLICATION ANALYSIS
6.4.4.2. TOP COUNTRY ANALYSIS
6.4.4.2.1. LATIN AMERICA
6.4.4.2.1.1. MARKET ESTIMATIONS AND FORECASTS 2014-2022 ($ MILLION)
6.4.4.2.1.2. MARKET REVENUES 2014-2022 ($ MILLION)
6.4.4.2.1.3. PRICE ANALYSIS
6.4.4.2.1.4. TOP PLAYERS & KEY PRODUCTS
6.4.4.2.1.5. KEY CONCLUSIONS
6.4.4.2.2. MIDDLE EAST & AFRICA
6.4.4.2.2.1. MARKET ESTIMATIONS AND FORECASTS 2014-2022 ($ MILLION)
6.4.4.2.2.2. MARKET REVENUES 2014-2022 ($ MILLION)
6.4.4.2.2.3. PRICE ANALYSIS
6.4.4.2.2.4. TOP PLAYERS & KEY PRODUCTS
6.4.4.2.2.5. KEY CONCLUSIONS
6.4.4.2.3. AFRICA
6.4.4.2.3.1. MARKET ESTIMATIONS AND FORECASTS 2014-2022 ($ MILLION)
6.4.4.2.3.2. MARKET REVENUES 2014-2022 ($ MILLION)
6.4.4.2.3.3. PRICE ANALYSIS
6.4.4.2.3.4. TOP PLAYERS & KEY PRODUCTS
6.4.4.2.3.5. KEY CONCLUSIONS
7. COMPANY PROFILES
7.1. ACCELERYS INC.
7.1.1. OVERVIEW
7.1.2. PRODUCT PORTFOLIO
7.1.3. KEY INNOVATION SECTOR
7.1.4. STRATEGIC INITIATIVES
7.1.5. SCOT ANALYSIS
7.2. AFFYMETRIX
7.2.1. OVERVIEW
7.2.2. PRODUCT PORTFOLIO
7.2.3. KEY INNOVATION SECTOR
7.2.4. STRATEGIC INITIATIVES
7.2.5. SCOT ANALYSIS
7.3. AGILENT TECHNOLOGIES
7.3.1. OVERVIEW
7.3.2. PRODUCT PORTFOLIO
7.3.3. KEY INNOVATION SECTOR
7.3.4. STRATEGIC INITIATIVES
7.3.5. SCOT ANALYSIS
7.4. CELERA CORPORATION
7.4.1. OVERVIEW
7.4.2. PRODUCT PORTFOLIO
7.4.3. KEY INNOVATION SECTOR
7.4.4. STRATEGIC INITIATIVES
7.4.5. SCOT ANALYSIS
7.5. DNANEXUS
7.5.1. OVERVIEW
7.5.2. PRODUCT PORTFOLIO
7.5.3. KEY INNOVATION SECTOR
7.5.4. STRATEGIC INITIATIVES
7.5.5. SCOT ANALYSIS
7.6. FOREST LABORATORIES INC.,
7.6.1. OVERVIEW
7.6.2. PRODUCT PORTFOLIO
7.6.3. KEY INNOVATION SECTOR
7.6.4. STRATEGIC INITIATIVES
7.6.5. SCOT ANALYSIS
7.7. GENEVA BIOINFORMATICS
7.7.1. OVERVIEW
7.7.2. PRODUCT PORTFOLIO
7.7.3. KEY INNOVATION SECTOR
7.7.4. STRATEGIC INITIATIVES
7.7.5. SCOT ANALYSIS
7.8. GVK BIOSCIENCES
7.8.1. OVERVIEW
7.8.2. PRODUCT PORTFOLIO
7.8.3. KEY INNOVATION SECTOR
7.8.4. STRATEGIC INITIATIVES
7.8.5. SCOT ANALYSIS
7.9. IBM LIFE SCIENCES
7.9.1. OVERVIEW
7.9.2. PRODUCT PORTFOLIO
7.9.3. KEY INNOVATION SECTOR
7.9.4. STRATEGIC INITIATIVES
7.9.5. SCOT ANALYSIS
7.10. ILLUMINA INC.
7.10.1. OVERVIEW
7.10.2. PRODUCT PORTFOLIO
7.10.3. KEY INNOVATION SECTOR
7.10.4. STRATEGIC INITIATIVES
7.10.5. SCOT ANALYSIS
7.11. JANSSEN PHARMACEUTICALS INC.,
7.11.1. OVERVIEW
7.11.2. PRODUCT PORTFOLIO
7.11.3. KEY INNOVATION SECTOR
7.11.4. STRATEGIC INITIATIVES
7.11.5. SCOT ANALYSIS
7.12. LIFE TECHNOLOGIES CORPORATION
7.12.1. OVERVIEW
7.12.2. PRODUCT PORTFOLIO
7.12.3. KEY INNOVATION SECTOR
7.12.4. STRATEGIC INITIATIVES
7.12.5. SCOT ANALYSIS
7.13. NOVARTIS PHARMACEUTICAL CORPORATION
7.13.1. OVERVIEW
7.13.2. PRODUCT PORTFOLIO
7.13.3. KEY INNOVATION SECTOR
7.13.4. STRATEGIC INITIATIVES
7.13.5. SCOT ANALYSIS
7.14. PFIZER INC.,
7.14.1. OVERVIEW
7.14.2. PRODUCT PORTFOLIO
7.14.3. KEY INNOVATION SECTOR
7.14.4. STRATEGIC INITIATIVES
7.14.5. SCOT ANALYSIS
7.15. SIEGEN INC.,
7.15.1. OVERVIEW
7.15.2. PRODUCT PORTFOLIO
7.15.3. KEY INNOVATION SECTOR
7.15.4. STRATEGIC INITIATIVES
7.15.5. SCOT ANALYSIS
LIST OF TABLES
GLOBAL ACOUSTIC INSULATION MARKET BY PHARMACOLOGICAL TREATMENT ($ MILLION)
GLOBAL CHOLINESTERASE INHIBITORS MARKET BY GEOGRAPHY ($ MILLION)
GLOBAL DONEPEZIL MARKET BY GEOGRAPHY ($ MILLION)
GLOBAL GALANTAMINE MARKET BY GEOGRAPHY ($ MILLION)
GLOBAL RIVASTIGMINE MARKET BY GEOGRAPHY ($ MILLION)
GLOBAL MEMANTINE MARKET BY GEOGRAPHY ($ MILLION)
GLOBAL NIMODIPINE MARKET BY GEOGRAPHY ($ MILLION)
GLOBAL HYDERGINE MARKET BY GEOGRAPHY ($ MILLION)
GLOBAL CYTIDINE -DIPHOSPHOCHOLINE (CDP-CHOLINE) MARKET BY GEOGRAPHY ($ MILLION)
GLOBAL OTHER DRUG CLASSES MARKET BY GEOGRAPHY ($ MILLION)
GLOBAL MULTI INFARCT DEMENTIA BY CAUSES OF DEMENTIA ($ MILLION)
GLOBAL MULTI INFARCT DEMENTIA BY ANEMIA BY GEOGRAPHY ($ MILLION)
GLOBAL MULTI INFARCT DEMENTIA BY BRAIN TUMOR BY GEOGRAPHY ($ MILLION)
GLOBAL MULTI INFARCT DEMENTIA BY CHRONIC INFECTION BY GEOGRAPHY ($ MILLION)
GLOBAL MULTI INFARCT DEMENTIA BY DEPRESSION BY GEOGRAPHY ($ MILLION)
GLOBAL MULTI INFARCT DEMENTIA BY THYROID DISEASE BY GEOGRAPHY ($ MILLION)
GLOBAL MULTI INFARCT DEMENTIA BY VITAMIN DEFICIENCY BY GEOGRAPHY ($ MILLION)
GLOBAL MULTI INFARCT DEMENTIA BY DRUG INTOXICATION BY GEOGRAPHY ($ MILLION)
NORTH AMERICA MULTI INFARCT DEMENTIA ($ MILLION)
EUROPE MULTI INFARCT DEMENTIA ($ MILLION)
ASIA PACIFIC MULTI INFARCT DEMENTIA ($ MILLION)
REST OF THE WORLD MULTI INFARCT DEMENTIA ($ MILLION)
LIST OF FIGURES
GLOBAL MULTI INFARCT DEMENTIA BY CHOLINESTERASE INHIBITORS ($ MILLION)
GLOBAL MULTI INFARCT DEMENTIA BY DONEPEZIL ($ MILLION)
GLOBAL MULTI INFARCT DEMENTIA BY GALANTAMINE ($ MILLION)
GLOBAL MULTI INFARCT DEMENTIA BY RIVASTIGMINE ($ MILLION)
GLOBAL MULTI INFARCT DEMENTIA BY MEMANTINE ($ MILLION)
GLOBAL MULTI INFARCT DEMENTIA BY NIMODIPINE ($ MILLION)
GLOBAL MULTI INFARCT DEMENTIA BY HYDERGINE ($ MILLION)
GLOBAL MULTI INFARCT DEMENTIA BY CYTIDINE -DIPHOSPHOCHOLINE (CDP-CHOLINE) ($ MILLION)
GLOBAL MULTI INFARCT DEMENTIA BY ANEMIA ($ MILLION)
GLOBAL MULTI INFARCT DEMENTIA BY BRAIN TUMOR ($ MILLION)
GLOBAL MULTI INFARCT DEMENTIA BY CHRONIC INFECTION ($ MILLION)
GLOBAL MULTI INFARCT DEMENTIA BY DEPRESSION ($ MILLION)
GLOBAL MULTI INFARCT DEMENTIA BY THYROID DISEASE ($ MILLION)
GLOBAL MULTI INFARCT DEMENTIA BY VITAMIN DEFICIENCY ($ MILLION)
GLOBAL MULTI INFARCT DEMENTIA BY DRUG INTOXICATION ($ MILLION)
UNITED STATES (U.S.) MULTI INFARCT DEMENTIA ($ MILLION)
CANADA MULTI INFARCT DEMENTIA ($ MILLION)
UNITED KINGDOM (UK) MULTI INFARCT DEMENTIA ($ MILLION)
FRANCE MULTI INFARCT DEMENTIA ($ MILLION)
GERMANY MULTI INFARCT DEMENTIA ($ MILLION)
ROE MULTI INFARCT DEMENTIA ($ MILLION)
INDIA MULTI INFARCT DEMENTIA ($ MILLION)
CHINA MULTI INFARCT DEMENTIA ($ MILLION)
JAPAN MULTI INFARCT DEMENTIA ($ MILLION)
ROAPAC MULTI INFARCT DEMENTIA ($ MILLION)
LATIN AMERICA MULTI INFARCT DEMENTIA ($ MILLION)
MENA MULTI INFARCT DEMENTIA ($ MILLION)
AFRICA MULTI INFARCT DEMENTIA 2014-2022 ($ MILLION)

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report